Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of the Korean Neurological Association ; : 71-76, 2005.
Article in Korean | WPRIM | ID: wpr-196874

ABSTRACT

BACKGROUND: Although relapses are known to be common in optic neuritis, there are only a few follow-up studies concerning recurrent optic neuritis. The aim of this study is to characterize the difference between monophasic and recurrent optic neuritis by analyzing clinical and laboratory spectrums of index event. METHODS: We performed a partially retrospective and prospective cohort study of patients with optic neuritis. The patients with optic neuritis were included by review of their medical records and neuroimaging studies and then followed up for the relapses of optic neuritis. Excluded were those who showed any evidence of multiple sclerosis, and those with prior demyelinating attacks. RESULTS: Thirteen of 43 enrolled patients had a recurrent optic neuritis during a mean (SD) follow up period of 58.0 (21.2) months, yielding a 5-year cumulative rate of recurrence of 39.5 percent. The patients who had CSF pleocytosis were more likely to develop a recurrent attacks (P<0.05), but neither clinical findings nor the other laboratory results appeared to influence recurrence. CONCLUSIONS: We suggest that this disorder have a distinctive feature in terms of relapse and CSF pleocytosis compared with monophasic optic neuritis.


Subject(s)
Humans , Cohort Studies , Follow-Up Studies , Leukocytosis , Medical Records , Multiple Sclerosis , Neuroimaging , Optic Neuritis , Prospective Studies , Recurrence , Retrospective Studies
2.
Journal of Korean Medical Science ; : 299-300, 2003.
Article in English | WPRIM | ID: wpr-210094

ABSTRACT

Flumazenil, an imidazobenzodiazepine, is the first benzodiazepine antagonist and is being used to reverse the adverse pharmacological effects of benzodiazepine. There have been a few reports on the central nevous system side effects with its use. We report a patient with generalized ballism following administration of flumazenil. The mechanism through which flumazenil induced this symptom is unknown. It is conceivable that flumazenil may antagonize the GABA-benzodiazepine receptor complex and induce dopamine hypersensitivity, thus induce dyskinesic symptoms.


Subject(s)
Female , Humans , Middle Aged , Diagnosis, Differential , Dyskinesias/etiology , Flumazenil/adverse effects , GABA Modulators/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL